Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01232569
Registration number
NCT01232569
Ethics application status
Date submitted
1/11/2010
Date registered
2/11/2010
Date last updated
29/07/2015
Titles & IDs
Public title
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Query!
Scientific title
A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Query!
Secondary ID [1]
0
0
2010-019912-18
Query!
Secondary ID [2]
0
0
NA25220
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tocilizumab 162 mg
Treatment: Drugs - Placebo
Experimental: Tocilizumab 162 mg sc - Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
Placebo comparator: Placebo sc - Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
Treatment: Drugs: Tocilizumab 162 mg
Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
Treatment: Drugs: Placebo
Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24
Query!
Assessment method [1]
0
0
A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity \[symptom-free and no arthritis symptoms\], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate).
Query!
Timepoint [1]
0
0
Baseline to Week 24
Query!
Secondary outcome [1]
0
0
Percentage of Patients With ACR50 and ACR70 Responses at Week 24
Query!
Assessment method [1]
0
0
A patient had an ACR50 response if there was at least a 50% improvement in the ACR scores. A patient had an ACR70 response if there was at least a 70% improvement in the ACR scores.
Query!
Timepoint [1]
0
0
Baseline to Week 24
Query!
Secondary outcome [2]
0
0
Time to Onset of ACR20, ACR50, and ACR70 Responses
Query!
Assessment method [2]
0
0
Time to first ACR response was calculated as the number of days between the date of the first ACR response minus the date of the first dose of study drug. Median days are reported.
Query!
Timepoint [2]
0
0
Baseline to Week 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 24
Query!
Assessment method [3]
0
0
Joints (28 joints) will be assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination.
Query!
Timepoint [3]
0
0
Baseline to Week 24
Query!
Secondary outcome [4]
0
0
Change From Baseline in C-reactive Protein at Week 24
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline to Week 24
Query!
Secondary outcome [5]
0
0
Change From Baseline in Erythrocyte Sedimentation Rate at Week 24
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline to Week 24
Query!
Secondary outcome [6]
0
0
Change From Baseline in the Patient's and the Physician's Global Assessment of Disease Activity Visual Analog (VAS) Score
Query!
Assessment method [6]
0
0
Patients and physicians assessed the patient's disease activity in the previous 24 hours on a 100 mm visual analog scale, where the extreme left end of the line represented "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end represented "maximum disease activity". Scores ranged from 0 to 100 with a higher score indicating more disease activity. A negative change score indicated less disease activity.
Query!
Timepoint [6]
0
0
Baseline to Week 24
Query!
Secondary outcome [7]
0
0
Change From Baseline in the Patient's Pain Visual Analog Score
Query!
Assessment method [7]
0
0
Patients assessed their pain in the previous 24 hours on a visual analog scale, where the extreme left end of the line represented "no pain" and the extreme right end represented "unbearable pain". Scores ranged from 0 to 100 with a higher score indicating more pain. A negative change score indicated less pain.
Query!
Timepoint [7]
0
0
Baseline to Week 24
Query!
Secondary outcome [8]
0
0
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
Query!
Assessment method [8]
0
0
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Patients completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Query!
Timepoint [8]
0
0
Baseline to Week 24
Query!
Secondary outcome [9]
0
0
Percentage of Patients With an Improvement of = 0.3 Units From Baseline in the HAQ-DI Score at Week 24
Query!
Assessment method [9]
0
0
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Patients completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Query!
Timepoint [9]
0
0
Baseline to Week 24
Query!
Secondary outcome [10]
0
0
Change From Baseline in Disease Activity Score 28 (DAS28) at Week 24
Query!
Assessment method [10]
0
0
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × v(TJC28)) + (0.28 × v(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Query!
Timepoint [10]
0
0
Baseline to Week 24
Query!
Secondary outcome [11]
0
0
Percentage of Patients With a DAS28 Score = 3.2 (DAS28 Low Disease Activity) at Week 24
Query!
Assessment method [11]
0
0
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × v(TJC28)) + (0.28 × v(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Query!
Timepoint [11]
0
0
Baseline to Week 24
Query!
Secondary outcome [12]
0
0
Percentage of Patients With a DAS28 Score < 2.6 (DAS28 Remission) at Week 24
Query!
Assessment method [12]
0
0
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × v(TJC28)) + (0.28 × v(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Query!
Timepoint [12]
0
0
Week 24
Query!
Secondary outcome [13]
0
0
Percentage of Patients With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses at Week 24
Query!
Assessment method [13]
0
0
Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score = 3.2, a change from baseline of \< -1.2 was a good response, \< -0.6 to = -1.2 was a moderate response, and = -0.6 was no response. For a post-baseline score \> 3.2 to = 5.1, a change from baseline of \< -0.6 was a moderate response and = -0.6 was no response. For a post-baseline score \> 5.1, a change from baseline \< -1.2 was a moderate response and = -1.2 was no response. A good response could not be achieved for post-baseline scores \> 3.2.
Query!
Timepoint [13]
0
0
Baseline to Week 24
Query!
Secondary outcome [14]
0
0
Change From Baseline in the Van Der Heijde Modified Sharp Radiographic Score at Week 24
Query!
Assessment method [14]
0
0
The degree of joint damage was assessed using the van der Heijde modified total Sharp score (mTSS). The methodology quantifies the extent of bone erosions for 44 joints and joint space narrowing (JSN) for 42 joints, with higher scores representing greater damage. The independent read of X-ray images was performed by 2 primary readers. In case of discrepancy between the 2 primary readers, an adjudicator was involved. The mTSS can range from 0 to 448 with a higher score indicating more joint damage. A negative change score indicates improvement.
Query!
Timepoint [14]
0
0
Baseline to Week 24
Query!
Secondary outcome [15]
0
0
Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey at Week 24
Query!
Assessment method [15]
0
0
The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.
Query!
Timepoint [15]
0
0
Baseline to Week 24
Query!
Secondary outcome [16]
0
0
Change From Baseline in Hemoglobin at Week 24
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Baseline to Week 24
Query!
Eligibility
Key inclusion criteria
* Adult patients, = years of age.
* Moderate to severe rheumatoid arthritis of = 6 months duration.
* Receiving treatment on an outpatient basis.
* Swollen joint count (SJC) = 6 (66 joint count) and tender joint count (TJC)= 8 (68 joint count) at screening and study start.
* On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
* Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.
* Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
* Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.
* Prior history of or current inflammatory joint disease other than rheumatoid arthritis.
* History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations.
Other inclusion and exclusion criteria applied to the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
656
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Cairns
Query!
Recruitment hospital [2]
0
0
- Kogarah
Query!
Recruitment postcode(s) [1]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Mississippi
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nebraska
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Córdoba
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
San Miguel de Tucuman
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Curitiba
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Goiania
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Juiz de Fora
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Porto Alegre
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Rio de Janeiro
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Salvador
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Sao Paulo
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
São Paulo
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Vitoria
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Plovdiv
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Sofia
Query!
Country [33]
0
0
Bulgaria
Query!
State/province [33]
0
0
Varna
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Alberta
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Manitoba
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Ontario
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Quebec
Query!
Country [38]
0
0
Colombia
Query!
State/province [38]
0
0
Bogota
Query!
Country [39]
0
0
Colombia
Query!
State/province [39]
0
0
Chia-cundinamarca
Query!
Country [40]
0
0
Colombia
Query!
State/province [40]
0
0
Medellin
Query!
Country [41]
0
0
Greece
Query!
State/province [41]
0
0
Athens
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Thessaloniki
Query!
Country [43]
0
0
Guatemala
Query!
State/province [43]
0
0
Guatemala City
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Debrecen
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Ashkelon
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Beer Sheva
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Haifa
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Ramat Gan
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Rishon Lezion
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Tel Aviv
Query!
Country [52]
0
0
Malaysia
Query!
State/province [52]
0
0
Batu Caves
Query!
Country [53]
0
0
Malaysia
Query!
State/province [53]
0
0
Kota Kinabalu
Query!
Country [54]
0
0
Malaysia
Query!
State/province [54]
0
0
Kuala Lumpur
Query!
Country [55]
0
0
Mexico
Query!
State/province [55]
0
0
Chihuahua
Query!
Country [56]
0
0
Mexico
Query!
State/province [56]
0
0
Culiacan
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Guadalajara
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Leon
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
Merida
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Mexicali
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Mexico
Query!
Country [62]
0
0
Mexico
Query!
State/province [62]
0
0
Morelia
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Obregon
Query!
Country [64]
0
0
Mexico
Query!
State/province [64]
0
0
Queretaro
Query!
Country [65]
0
0
New Zealand
Query!
State/province [65]
0
0
Otahuhu
Query!
Country [66]
0
0
Panama
Query!
State/province [66]
0
0
Panama City
Query!
Country [67]
0
0
Philippines
Query!
State/province [67]
0
0
Cebu
Query!
Country [68]
0
0
Philippines
Query!
State/province [68]
0
0
Davao
Query!
Country [69]
0
0
Philippines
Query!
State/province [69]
0
0
Manila
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Bytom
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Dzialdowo
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Elblag
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Koscian
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Krakow
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Torun
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Warszawa
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Kemerovo
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Moscow
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Novosibirsk
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Petrozavodsk
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Ryazan
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Saint-petersburg
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
St Petersburg
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
UFA
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Voronezh
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Durban
Query!
Country [87]
0
0
South Africa
Query!
State/province [87]
0
0
Pinelands
Query!
Country [88]
0
0
South Africa
Query!
State/province [88]
0
0
Pretoria
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
La Coruna
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Oviedo
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Sevilla
Query!
Country [92]
0
0
Switzerland
Query!
State/province [92]
0
0
Fribourg
Query!
Country [93]
0
0
Switzerland
Query!
State/province [93]
0
0
Genève
Query!
Country [94]
0
0
Switzerland
Query!
State/province [94]
0
0
Lausanne
Query!
Country [95]
0
0
Switzerland
Query!
State/province [95]
0
0
Zürich
Query!
Country [96]
0
0
Thailand
Query!
State/province [96]
0
0
Bangkok
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01232569
Query!
Trial related presentations / publications
Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01232569
Download to PDF